Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine
Cysneiros RM, Farkas D, Harmatz JS, von Moltke LL, Greenblatt DJ
Clinical pharmacology and therapeutics · 40 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institute on Aging
- Gobierno
- National Institute of Mental Health
- Gobierno
- National Institute on Drug Abuse
- Gobierno
- National Institute of Allergy and Infectious Diseases
- Gobierno
- National Institute of Diabetes and Digestive and Kidney Diseases
- Gobierno
- National Center for Research Resources
- Gobierno
- National Center for Complementary and Integrative Health
- Gobierno
- NIAID NIH HHS
- Gobierno
- NIDA NIH HHS
- Gobierno
- NIDDK NIH HHS
- Gobierno
- NIMH NIH HHS
- Gobierno
- NIA NIH HHS
- Gobierno
- NCCIH NIH HHS
- Gobierno
- NCRR NIH HHS
- Subvenciones
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-058496); National Center for Research Resources (RR000054); National Institute on Aging (AG-017880); National Institute on Drug Abuse (DA-013834); National Institute of Mental Health (MH-058435); National Center for Complementary and Integrative Health (AT-001381); National Institute on Drug Abuse (DA-005258); National Center for Complementary and Integrative Health (AT 003540); National Institute of Allergy and Infectious Diseases (AI-058784)
Según 14 financiadores declarados.
Publicación
- Publicado
- 2007-04-18 · Clin Pharmacol Ther · vol. 82 · número 1 · págs. 54–62
- Editorial
- Wiley
- Citado
- 73 citas · más que el 94% de estudios similares · 4.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 61 trabajos
- Acceso
- De pago
- Áreas de investigación
- Coffee research and impacts · Pharmacogenetics and Drug Metabolism · Sleep and related disorders
- Palabras clave
- zolpidem, caffeine, drug interactions, pharmacokinetics, pharmacodynamics, sedation, cognitive impairment, benzodiazepine receptor agonists, plasma concentration, reaction time, delayed recall
- MeSH
- humans, pyridines, caffeine, hypnotics and sedatives, central nervous system stimulants, electroencephalography, administration, oral, cross-over studies, double-blind method, cognition, mental recall, reaction time, sleep, drug interactions, adult, female, male, zolpidem
5 autores
- Roberta Monterazzo Cysneiros🇺🇸Tufts University; Tufts Medical Center
- Dóra Farkas🇺🇸Tufts University; Tufts Medical Center
- Jerold S. Harmatz🇺🇸Tufts University; Tufts Medical Center
- Lisa Lvon Moltke🇺🇸Tufts University; Tufts Medical Center
- David J. Greenblatt🇺🇸 · autor de correspondenciaTufts University; Tufts Medical Center
Resumen
El texto original del estudio, en el idioma en que se publicó.
The kinetic and dynamic interaction of caffeine and zolpidem was evaluated in a double-blind, single-dose, six-way crossover study of 7.5 mg zolpidem (Z) or placebo (P) combined with low-dose caffeine (250 mg), high-dose caffeine (500 mg), or placebo. Caffeine coadministration modestly increased maximum plasma concentration (C(max)) and area under the plasma concentration-time curve of zolpidem by 30-40%, whereas zolpidem did not significantly affect the pharmacokinetics of caffeine or its metabolites. Compared to P+P, Z+P significantly increased sedation, impaired digit-symbol substitution test performance, slowed tapping speed and reaction time, increased EEG relative beta amplitude, and impaired delayed recall. Caffeine partially, but not completely, reversed most pharmacodynamic effects of zolpidem. Thus, caffeine only incompletely reverses zolpidem's sedative and performance-impairing effects, and cannot be considered as an antidote to benzodiazepine agonists.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.